The public offering of MiniMax (00100.HK) is scheduled to close at 12:00 noon today (January 6). Data shows that the public offering tranche has recorded an over-subscription rate of around 1,350.75 times, with margin financing funds reaching approximately HK$283.143 billion. The company is expected to be listed on the Main Board of the Hong Kong Stock Exchange on January 9.
As of 10:46 on January 6, 2026, Communication ETF (515880) fell 2.29%, with the latest quote at 3.07 yuan.
Beijing Roborock Technology has obtained CSRC filing approval for its proposed Hong Kong IPO of up to 33,108,000 shares. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
Shaanxi Tourism Culture Industry Co., Ltd. will be listed on the Shanghai Main Board on January 6, 2026, with an issue price of RMB 80.44 per share. As a Shaanxi provincial state-owned assets-controlled cultural tourism enterprise, the company's core revenue comes from the renowned performance project "The Song of Everlasting Regret". The funds raised from this listing will be used for project acquisitions and the expansion of its performance model replication in other regions.
EVE Energy Co., Ltd. (300014.SZ) formally submitted an application for a main board listing on the Hong Kong Stock Exchange on January 2, with CITIC Securities acting as the sole sponsor. The company is one of the few globally integrated lithium battery platform enterprises covering consumer, power, and energy storage batteries across all application scenarios. In 2024, it ranked second globally in energy storage battery shipments, while also maintaining leading positions in the consumer and power battery sectors.
On December 30, 2025, Insilico Medicine, hailed as "the first AI-driven pharmaceutical stock on the Hong Kong stock market" and a strategic investment of the Hong Kong Investment Corporation Limited (HKIC), was listed on the Main Board of the Hong Kong Exchanges and Clearing Limited (HKEX). With a total fundraising of HK$2.277 billion, it has claimed the title of the largest IPO in the biopharmaceutical sector of the Hong Kong stock market in 2025, and its share price delivered an impressive performance on the debut day. It is reported that Biren Technology, another portfolio company of HKIC, is also set to list on the HKEX on January 2, 2026, which indicates that the effectiveness of HKIC’s diversified strategic investment layout continues to unfold.
